Abstract
Summary
Drug Discovery Services Market research report Forecast to 2030
Market Overview
The Drug Discovery Services market industry is projected to exhibit a significant CAGR of 13.92% during the forecast period. Developing Re-appropriating of Drug Advancement and Expanding Exploration and Improvement Expenses are the key market drivers upgrading the Drug Discovery Services market development.
Drug and biopharmaceutical organizations are picking completely coordinated or practical rethinking services for drug innovative work from the early improvement stage to the late-stage advancement stage due to expanded Research and development consumptions. While drug organizations are under extraordinary strain to monitor fixed costs, re-appropriating has arisen as a strategic answer for the absence of inside assets required for new item improvement. Enormous pharma firms are changing to a more streamlined corporate methodology that unequivocally stresses rethinking.
Expanding need for imaginative therapeutics across a scope of restorative objectives. Drug-finding services Rising requirement for imaginative therapies for constant sicknesses and headways in the medical care industry are anticipated to be the primary drivers of market development. Drug and biopharmaceutical organizations actually contract their innovative work (Research and Development) activities to CROs, who offer Research and development services and make commitment models to boost Research and development productivity. Legislatures and drug enterprises are compelled to search for answers and lift their interest in clinical preliminaries because of the expanded weight of persistent sicknesses. Subsequently, there will be a more prominent requirement for drug discovery services.
Market Segmentation
Based on Drug Type, the Drug Discovery Services market has been classified into Small Molecule Drugs, Biologics’ Based on type, the market is divided into Drug metabolism and pharmacokinetics (DMPK) Services, Pharmaceutical Services, and Others. Therapeutic Areas of the Drug Discovery Services market are bifurcated into data into Oncology, Others.
Regional Analysis
North America is likely to drive the global Drug Discovery Services market due to the higher interest in drug discovery Research and development, critical firms with laid-out research foundations, and specialized upgrades. As rethinking is at this point not just about reducing expenses, a developing requirement for viability, quality, and development is expected to help industry extension.
The Asia Pacific drug discovery services market is anticipated to develop the highest growth owing to the accessibility of qualified individuals, less expensive costs, a successful administrative climate, and great information, the Region is rapidly turning into a center for re-appropriating drug improvement exercises. The second-biggest drug market on the planet, Japan, is expected to furnish CROs with a sizable potential, driving the business.
The fast improvement of innovation and the development of metropolitan regions impel the European drug discovery services market. The improvement of biologics and biosimilars has seen an expansion in speculation from biopharmaceutical firms, which is liable for the ascent in the number of approved drugs in Europe. The European drug discovery services market is expected to be driven by expanding consumptions made by many significant organizations in different clinical and non-clinical examination exercises that are moved to a few CRO specialist co-ops and help with proficient item improvement.
Major Players
Abbott Laboratories Inc., Advinus Therapeutics, Albany Molecular Research Inc. (AMRI), Aurigene, Agilent Technologies Ubiquigent, AstraZeneca PLC, Retrogenix (U.K.), Charles River Laboratories International, Eurofins, and Liverpool ChiroChem Ltd.
Table of Contents
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING RESEARCH & DEVELOPMENT EXPENDITURE
4.2.2 RISING DRUG DEVELOPMENT OUTSOURCING
4.3 RESTRAINTS
4.3.1 STRINGENT REGULATORY POLICIES AND COSTS ASSOCIATED TO DRUG DISCOVERY
4.4 OPPORTUNITY
4.4.1 TECHNOLOGICAL ADVANCEMENTS IN DRUG DISCOVERY
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)
5.1.2 SERVICE CUSTOMIZATION
- 5.1.2.1 R&D
- 5.1.2.2 GOOD LABORATORY PRACTICES (GLP)
5.1.3 CUSTOMER PURCHASE SUPPORT
5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 COVID-19 IMPACT ON THE DRUG DISCOVERY SERVICES MARKET
5.3.1 IMPACT ON R&D
5.3.2 IMPACT ON PRICING
5.3.3 IMPACT ON MARKET GROWTH
6 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE
6.1 OVERVIEW
6.2 SMALL MOLECULE DRUG
6.3 BIOLOGICS DRUG
7 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TYPES OF SERVICES
7.1 OVERVIEW
7.2 DRUG METABOLISM AND PHARMACOKINETICS (DMPK) SERVICES
7.3 PHARMACEUTICAL SERVICES
7.4 MEDICINAL CHEMISTRY
7.5 BIOLOGICAL SERVICES
7.6 MEDICATION
8 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA
8.1 OVERVIEW
8.2 ONCOLOGY
8.3 CARDIOVASCULAR DISEASES
8.4 RESPIRATORY DISEASES
8.5 DIABETES
8.6 OTHERS
9 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY TECHNOLOGY
9.1 OVERVIEW
9.2 HIGH THROUGHPUT SCREENING
9.3 BIOCHIPS
9.4 PHARMACOGENOMICS AND PHARMACOGENETICS
9.5 METABOLOMICS
9.6 OTHERS
10 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY END USER
10.1 OVERVIEW
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3 RESEARCH & ACADEMIC INSTITUTES
10.4 OTHERS
11 GLOBAL DRUG DISCOVERY SERVICES MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 AUSTRALIA
11.4.5 SOUTH KOREA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST
11.5.2 AFRICA
11.5.3 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 MAJOR GROWTH STRATEGY IN DRUG DISCOVERY SERVICES MARKET
12.4 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN DRUG DISCOVERY SERVICES MARKET
12.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.5.1 SERVICE LAUNCH
12.5.2 MERGERS & ACQUISITIONS
12.5.3 PARTNERSHIP/COLLABORATION
12.6 MAJOR PLAYERS SALES ANALYSIS
12.6.1 SALES & OPERATING INCOME, 2021 (USD MILLION)
12.6.2 MAJOR PLAYERS R&D ANALYSIS, 2021 (USD MILLION)
13 COMPANY PROFILE
13.1 THERMO FISHER SCIENTIFIC INC
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 SERVICES OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 ARAGEN LIFE SCIENCES PVT. LTD
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 SERVICES OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 KEY STRATEGIES
13.3 PIRAMAL PHARMA SOLUTIONS
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 SERVICES OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 KEY STRATEGIES
13.4 CURIA GLOBAL, INC
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 SERVICES OFFERED
13.4.4 KEY STRATEGIES
13.5 CHARLES RIVER LABORATORIES
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 SERVICES OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 EUROFINS SCIENTIFIC
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 SERVICES OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 SWOT ANALYSIS
13.6.6 KEY STRATEGIES
13.7 IQVIA
13.7.1 COMPANY OVERVIEW
13.7.2 FINANCIAL OVERVIEW
13.7.3 SERVICES OFFERED
13.7.4 KEY DEVELOPMENTS
13.7.5 SWOT ANALYSIS
13.7.6 KEY STRATEGIES
13.8 EVOTEC
13.8.1 COMPANY OVERVIEWS
13.8.2 FINANCIAL OVERVIEW
13.8.3 SERVICES OFFERED
13.8.4 KEY DEVELOPMENTS
13.8.5 KEY STRATEGIES
13.9 WUXI APPTEC CO., LTD
13.9.1 COMPANY OVERVIEW
13.9.2 FINANCIAL OVERVIEW
13.9.3 SERVICES OFFERED
13.9.4 KEY DEVELOPMENTS
13.9.5 SWOT ANALYSIS
13.9.6 KEY STRATEGIES
13.10 LABORATORY CORPORATION OF AMERICA HOLDINGS
13.10.1 COMPANY OVERVIEW
13.10.2 SERVICES OFFERED
13.10.3 KEY DEVELOPMENTS
13.10.4 KEY STRATEGIES
13.11 SELVITA
13.11.1 COMPANY OVERVIEW
13.11.2 FINANCIAL OVERVIEW
13.11.3 SERVICES OFFERED
13.11.4 KEY DEVELOPMENTS
13.11.5 SWOT ANALYSIS
13.11.6 KEY STRATEGIES
13.12 SYGNATURE DISCOVERY
13.12.1 COMPANY OVERVIEW
13.12.2 FINANCIAL OVERVIEW
13.12.3 SERVICES OFFERED
13.12.4 KEY DEVELOPMENTS
13.12.5 SWOT ANALYSIS
13.12.6 KEY STRATEGIES
13.13 SYMERES
13.13.1 COMPANY OVERVIEW
13.13.2 FINANCIAL OVERVIEW
13.13.3 SERVICES OFFERED
13.13.4 KEY DEVELOPMENTS
13.13.5 SWOT ANALYSIS
13.13.6 KEY STRATEGIES
13.14 NUCHEM SCIENCES INC
13.14.1 COMPANY OVERVIEW
13.14.2 FINANCIAL OVERVIEW
13.14.3 SERVICES OFFERED
13.14.4 KEY STRATEGIES
13.15 PARAZA PHARMA, INC
13.15.1 COMPANY OVERVIEW
13.15.2 FINANCIAL OVERVIEW
13.15.3 SERVICES OFFERED
13.15.4 KEY DEVELOPMENTS
13.15.5 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS